Drug intelligence / Profile preview

REGEN-HEPS

Development stage: Preclinical
Lead developer: Satellite Bio
Modality: Cell Therapies
Administration: Implant, Parenteral

Overview

REGEN-HEPS is a cell therapy product consisting of expanded primary human hepatocytes (PHHs) developed by Satellite Bio. It is part of the company's Satellite Adaptive Tissue (SAT) platform, which aims to create implantable bioengineered tissues to restore organ function. REGEN-HEPS is produced through a proprietary expansion protocol that allows for significant scaling (over 1,000-fold) of donor-derived hepatocytes while maintaining their mature phenotype and functional capacities, including albumin secretion and metabolic activity. In preclinical models of liver disease, REGEN-HEPS demonstrated robust engraftment and survival benefits comparable to primary human hepatocytes, addressing the critical shortage of functional liver cells for therapeutic use.

Other names: REGEN-HEPS

Beyond the preview

Go deeper on REGEN-HEPS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGEN-HEPS.

Explore the full profile